Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Senzime AB ( (SE:SEZI) ) is now available.
Senzime AB has secured a 50 MSEK credit line facility from a consortium of existing shareholders, including Crafoord and Segulah, alongside DBT Capital of Noba Bank Group, on fair market terms. The financing is structured as a combination of a loan and a revolving credit facility to cover peaks in working capital needs, with no warrants or other dilutive instruments attached.
Management describes the facility as a strong vote of confidence in Senzime’s business model, scalability and global potential, underlining the long-term commitment of key shareholders and external financiers. The added liquidity is expected to support the company’s rapid growth trajectory, reinforcing its financial flexibility as it expands its neuromuscular monitoring solutions in a changing healthcare market.
The most recent analyst rating on (SE:SEZI) stock is a Sell with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime AB is a Swedish medical device company specializing in precision-based monitoring systems that enhance perioperative patient safety, improve clinical outcomes and reduce healthcare costs. Founded in 1999 and listed on Nasdaq Stockholm, the company’s flagship TetraGraph system provides best-in-class monitoring of neuromuscular transmission during surgery and is deployed in thousands of operating rooms worldwide.
Average Trading Volume: 224,964
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK785.3M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.